

AD _____

Award Number: W81XWH-04-1-0014

TITLE: Characterization of a Novel Intracellular Receptor for
Phorbol Esters and Diacylglycerol in Prostate Cancer

PRINCIPAL INVESTIGATOR: Jose Luis Oliva Martinez, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-6205

REPORT DATE: February 2005

TYPE OF REPORT: Annual Summary

20060215 120

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE February 2005	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Feb 2004 - 31 Jan 2005)	
4. TITLE AND SUBTITLE Characterization of a Novel Intracellular Receptor for Phorbol Esters and Diacylglycerol in Prostate Cancer			5. FUNDING NUMBERS W81XWH-04-1-0014	
6. AUTHOR(S) Jose Luis Oliva Martinez, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-6205 <i>E-Mail:</i> joseluis@spirit.gcrc.upenn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The small GTP-binding protein Rac controls essential functions, including actin cytoskeleton reorganization, cell proliferation, cell cycle progression, adhesion, migration and invasion. The relationship of Rac to prostate carcinogenesis has not been extensively studied. However upstream activators of Rac have been described to be hyperactivated in prostate cancer, and it is well known that growth factors are very important in the control of prostate cancer proliferation and progression, as well as in the maintenance of growth during androgen independency. Chimaerins, through their Rac-GAP activity, accelerate the hydrolysis of GTP from Rac, leading to its inactivation. To date four chimaerin isoforms have been isolated and reported: $\alpha 1$, $\alpha 2$ -, $\beta 1$ - and $\beta 2$ -Chimaerin. While $\alpha 1$ - and $\beta 1$ -chimaerin are restricted to brain and testis, respectively, $\alpha 2$ - and $\beta 2$ -chimaerin are widely expressed. No experimental information has been reported about the possible role of chimaerins in prostate cancer. Likewise, there are no information available about the expression of different chimaerin in prostate cancer cell lines. Our work hypothesis is that by inhibiting Rac function in prostate cancer cells, chimaerins will impair proliferation and reduce the invasive properties of prostate cancer cells.				
14. SUBJECT TERMS Rac, Rac-GAP, chimaerin				15. NUMBER OF PAGES 10
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	9
Appendices.....	None

INTRODUCTION

The small GTP-binding protein Rac controls essential functions, including actin cytoskeleton reorganization, cell proliferation, cell cycle progression, adhesion, migration and invasion. Whereas the relationship of Rac to prostate carcinogenesis has not been extensively studied, several papers have described that upstream activators of Rac are hyperactivated in prostate cancer, and it is well known that growth factors are very important in the control of prostate cancer proliferation and progression, as well as in the maintenance of growth during androgen independency. Rac belongs to the Rho family of small GTP-binding proteins, and cycles between an "on" (GTP-bound) and an "off" (GDP-bound) state, steps that involve guanine nucleotide exchange factors (GEFs) and GTPase activating proteins, which accelerate GTP hydrolysis, respectively (1-3)

Chimaerins, through their Rac-GAP activity, accelerate the hydrolysis of GTP from Rac1, leading to its inactivation. To date four chimaerin isoforms have been isolated: α 1, α 2-, β 1- and β 2-Chimaerin. While α 1- and β 1-chimaerin are restricted to brain and testis, respectively, α 2- and β 2-chimaerin are widely expressed (4,5). However, there are no reported information or experimental data describing chimaerin activity and/or expression in prostate cancer cells. Since chimaerins inhibit Rac function, it is predictable that they will have profound effects on Rac mediated signaling, and therefore impact on proliferation and invasion in prostate cancer cells.

BODY

Characterization of chimaerin isozymes in prostate cancer cells.

To determine which chimaerin isoforms are expressed in prostate cells, we initiated studies to determine their expression using non-quantitative RT-PCR. We used specific primers for the different chimaerin isoforms and GADPH based on the reported human sequences. We also initiated Western blot assays. We used LNCaP and C4 cells as androgen-dependent model with different sensitivities to androgens. The PC3 cell line was used in our experiments as a model for as an androgen-independent cells. Our experimental data using non-quantitative RT-PCR (Figure 1) showed that LNCaP cells do not express α 2- or β 2-chimaerin. C4 cells express only β 2-chimaerin at very low levels and PC3 cells express α 2- and β 2-chimaerin at similar levels.




Figure1. Non-quantitative RT-PCR of α 2-, β 2-chimaerin and GADPH in LNCaP, PC3 and C4 cells.

Since we have recently determined that our β 2-chimaerin antibody (rat monoclonal) cross-reacts with α 2-chimaerin (Figure 2), and both isoforms have the same molecular size, we designed a peptide based on the α 2-chimaerin sequence. This peptide was inoculated into rabbits. We are currently determining whether the antibody indeed detects α 2-chimaerin and hopefully should not cross-react with β 2-chimaerin, as a specific peptide was indeed designed for these experiments.




Figure 2. Rat chimaerin antibody used in western blot analysis for the detection of cross-reacts with α 2-chimaerin. Cell lysates from the human ovarian cancer cell line CP70, that express α 2- but not β 2-chimaerin and murine Neuro 2A cell line, that express both isoforms (Kazanietz lab, unpublished data), were analyzed for chimaerin expression.

Cloning of α 2 chimaerin.

As a cDNA for the α 2-chimaerin isoform was not available in our laboratory, and this would be needed not only for functional experiments as well as for the characterization of the antibody, we decided to clone this cDNA using RT-PCR. We used cDNA generated from fresh PC3 mRNA and by RT-PCR was carried out specific primers. Restriction sites have been included in order to facilitate subcloning into various expression vectors. We have been successful in cloning this chimaerin isoform and then we subcloned it into TOPO®- vector (Invitrogen). The identity of the cDNA was verified by sequencing. Results revealed 100% identity with the sequence reported in NCBI databases, suggesting that no mutations were introduced in the PCR reaction.

Generation of chimaerin adenoviruses.

The generation of recombinant adenoviruses to study the role of specific chimaerins represents an essential step, as we have developed conditions in our laboratory to achieve nearly ~100% of the prostate cancer cells expressing recombinant proteins. We normally use the AdEasyR system (Stratagene, La Jolla, CA) to generate adenoviruses. The multicloning site of this vector was previously modified in our laboratory to facilitate easy subcloning, and a N-terminal HA-tag has been included for easy detection. Previously, in our laboratory we have successfully generated adenoviruses for *wild type* β 2- chimaerin (β 2-chim-AdV) and the β 2-chimaerin GAP domain (β -GAP-AdV).

I have been actively involved in the generation of other adenoviruses that would be needed in our experiments, as follows:

β 2 chimaerin

AdVs for GAP inactive mutants: **β 2-chim- Δ EIE-AdV** and **β 2-chim-298RRR-AdV**.

AdVs for phorbol ester/DAG unresponsive chimaerins: **β 2-chim-C246A-AdV**.

AdVs for SH2 domain : **β 2-chim- Δ SH2-AdV**.

The β 2-chimaerin crystal structure of β 2-chimaerin has been recently reported, as part of a collaborative effort between our laboratory and the laboratory of Dr. Jim Hurley at the NIH (6). In this study it was found that several β 2-chimaerin mutants present high sensitivity to phorbol ester-induced translocation as well as enhanced RacGAP activity *in vivo*. Due to this important finding we decided to incorporate these mutants to our study, as they will greatly contribute to our functional studies. Thus, I have been actively involved in the generation of adenoviruses encoding for two active mutants: **β 2-chimaerin Q32A** and **β 2-chimaerin -I130A**.

α 2 chimaerin

We are currently generating the adenoviral construct for the generation of an adenovirus for *wild type α 2 chimaerin*: **α 2-chim-AdV**. Adenoviruses for active and inactive mutants are in the process of being generated.

Expression of chimaerins upon adenoviral infection.

Since all adenoviruses constructs have been designed with an epitope tag (HA-tag), we carried out infections in prostate cancer cells and determined whether they can be detected using an anti-HA antibody. Experimental data showed that all adenoviruses work successfully upon infection of prostate cancer cells, as well as in other cellular models. Chimaerin expression was detected 24 hours after infection. Although a careful time-course analysis has not been carried out, it is expected that expression should last for several days. This assumption is based on similar experiments that we have carried out using adenoviruses with the same adenoviral expression vector.

Cloning of a putative β 2-chimaerin promoter.

Transcription in eukaryotic cells is regulated at multiple levels. It has been determined that the methylation status of CpG islands in the gene directly affects the DNA-protein interactions. Most of the CpG islands in the promoter remain unmethylated, but when methylation occurs the associated gene is silenced. Thus, DNA methylation acts as a major epigenetic modification to maintain stable gene silencing. Aberrant DNA methylation impacts on gene transcription and it has been linked to cancer formation (7,8). Since several prostate cancer cell lines have low chimaerin expression, we sought to investigate whether the effect was at the promoter level. To date, there is no information on the promoter for β 2 chimaerin. In our laboratory we detected *in silico* a region in the β 2-chimaerin locus with promoter characteristics. This region contains a putative CpG island. A 1 Kb genomic DNA fragment 5' upstream from the β 2-chimaerin start codon was cloned by PCR into TOPO®- vector (Invitrogen).

Using PCR we have amplified and subcloned different fragments (see list above) of the 1 Kb genomic segment into plasmid pRTK-Luc (this is a construct that encodes for a luciferase gene under the control of a TK promoter). The constructs generated were as follows: **pR-81-Luc**, **pR-181-Luc**, **pR-281-Luc**, **pR-381-Luc**, **pR-481-Luc**, **pR-581-Luc**, **pR-1000-Luc** (the number represent the position of the first nucleotide upstream of the ATG). **pR-BASIC** (luciferase with no promoter) as a negative control and **pRTK-Luc** as a positive control.

We have transiently co-transfected these constructs together with a Renilla expression vector (for normalization) into several cell lines. Experimental data revealed that all constructs induce luciferase expression upon transfection (Figure 3). We are currently analyzing in a comparative manner the various constructs upon transfection into prostate cancer cells (as well as in other cell types).




Figure 3. Luciferase activity of different constructs of $\beta 2$ -chimaerin putative promoter in several cell lines. NIH3T3, Neuro2A, PC3, C4 and Cos1 cells were transfected with 0.5 μ g of each reporter construct, and 24 h after transfection luciferase activity of cell lysates was determined. Values represent the means $\pm$ S.D. from three different experiments.

In a different set of experiments we have focused on the methylation of the promoter. The constructs described above were methylated *in vitro* by using the enzymes SssI methylase, HpaII methylase and HhaI methylase. The methylation status was determined by digestion with the respective enzymes and visualization in an agarose gel (Figure 4a). In a preliminary experiment we observed that upon transfection of the methylated constructs no luciferase activity can be detected (Figure 4b). These results suggest that the 1 Kb fragment that we have isolated is indeed susceptible to methylation and therefore one may expect that methylation may greatly influence the expression of the gene in certain cancer cells, including prostate cancer cells.




Figure 4. Effect of *in vitro* methylation on β 2-chimaerin putative promoter activity. A, pR-BASIC and pRB-281 were methylated *in vitro* with HpaII methylase. The extent of methylation was assessed by comparing digestion patterns of unmethylated (lanes 2-4) and methylated (lanes 1-3) constructs with HpaII. B, methylated and unmethylated pR-BASIC and pR-281 constructs were transfected into Cos1 cells and assayed for luciferase activity. Values represent the means $\pm$ S.D. from three different experiments.

Future directions.

The next goals will be:

1. To assess whether chimaerins regulate mitogenic signaling in prostate cancer cells.
2. To determine how chimaerins affect cytoskeleton reorganization, migration and invasion in prostate cancer cells. The adenoviruses for different chimaerin isoforms and mutants will be used in these experiments.
3. To continue the characterization of the putative β 2-chimaerin promoter and to determine whether methylation is a critical factor in β 2 chimaerin expression.

KEY RESEARCH ACCOMPLISHMENTS

1. We have initiated the characterization of chimaerin isoform expression in prostate cancer cell lines.
2. We generated adenoviruses or adenoviral constructs that are essential for functional studies in prostate cancer cells.
3. We clone a 1 kB fragment that corresponds to the β 2-chimaerin promoter.
4. We generated reporter constructs for different regions of the β 2-chimaerin promoter, which will be used in luciferase assays.
5. We initiated studies aimed at determining whether the β 2-chimaerin promoter is regulated by methylation.

REPORTABLE OUTCOMES

None.

CONCLUSIONS

In the last year we initiated experiments to characterize the regulation and function of β 2-chimaerin and related chimaerin isoforms in prostate cancer cells. This protein regulates the function of the small GTP-binding protein Rac, which plays essential roles in mitogenesis, transformation, and the metastatic cascade. We have obtained preliminary data regarding the expression of chimaerin isozymes in prostate cancer cell lines. It seems that expression is low in prostate cancer cells, which is in agreement with data in other types of cancers, such as breast cancer cells (unpublished observations from our laboratory). Therefore, understanding the events that control the expression of the β 2-chimaerin gene is very important. The cloning of a putative promoter and its characterization will further enhance the understanding of the regulation of this molecule. In addition, in the present year we have successfully generated an important set of tools, in addition to those already available in the laboratory, such as adenoviruses for different chimaerin isoforms and mutants. We have successfully assessed and validated experimentally all these tools.

REFERENCES

1. Mackay, D.J., and Hall, A. Rho GTPases. *J. Biol. Chem.* 273: 20685-20688 (1998).
2. Bar-Sagi, D., and Hall, A. Ras and Rho GTPases: a family reunion. *Cell* 103: 227-238 (2000).
3. Ridley, A.J. Rho family proteins: coordinating cell responses. *Trends Cell Biol.* 11: 471-477 (2001).
4. Caloca, M.J., Wang, H.B., Delemos, A., Wang, S., and Kazanietz, M.G. Phorbol esters and related analogs regulate the subcellular localization of β 2-chimaerin, a non-PKC. phorbol ester receptor. *J. Biol. Chem.* 276: 18303-18312 (2001).

5. Wang, H., and Kazanietz, M.G. Chimaerins, novel .non-PKC. phorbol ester receptors, associate withTnp21-I (p23). Evidence for a novel anchoring mechanism involving the chimaerin C1 domain. *J. Biol.Chem.* 277: 4541-4550 (2002).
6. Canagarajah B, Leskow FC, Ho JY, Mischak H, Saidi LF, Kazanietz MG, Hurley JH. Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. *Cell.* 2004 119:407-418.
7. Jones PA: Epigenetics in carcinogenesis and cancer prevention. *Ann N Y Acad Sci* 2003, 983:213-219.
8. Feninberg A: Cancer epigenetics takes center stage. *Proc Natl Acad Sci USA* 2001, 98(2):392-394.)

APPENDICES

None.

ABBREVIATIONS

AdV: adenovirus
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
DAG: diacylglycerol
GAP: GTPase activating protein
Kb: Kilobase
MOI: Multiplicity of infection
NCBI: National Center for Biotechnology Information
PKC: protein kinase C
PMA: Phorbol 12-myristate 13-acetate
PCR: Polymerase Chain Reaction
Rac-GAP: Rac-GTPase activating protein
RT: Reverse Transcription
TK: Thymidine Kinase